Researchers have identified a set of genes, including DNMT3A, that could potentially be used to predict clinical outcomes of patients who suffer from a type of Acute Myeloid Leukemia (AML) associated with an FLT3 internal tandem duplication (FLT3-ITD) mutation.
ConclusionOur study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.
Authors: Chamoun K, Borthakur G
INTRODUCTION: Acute myeloid leukemia (AML) is the most common myeloid malignancy in adults. Despite recent discoveries of targeted therapies, the frontline therapy consisting of chemotherapy remains unchanged for the past four decades. Like other cancers, AML is characterized by deranged DNA damage repair (DDR) pathway. Although impaired DDR may contribute to the pathogenesis of AML it also allows leukemia cells with damaged DNA to attempt repair resulting in resistance. CHK1 inhibitors reverse the cell cycle arrest, disallowing the cell to repair the chemotherapy-induced DN…
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save…
The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia, Published online: 08 August 2018; doi:10.1038/s41375-018-0227-5The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia
Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger ones. Several factors contribute to the poor outcomes for this patient group.
Pharmacogenomics, Ahead of Print.
Standard therapy or improving standard therapy can make the majority of acute myeloid leukemia (AML) patients partly or complete remission. However, the treatment often relapses from remission. A small fraction of leukemic stem cells (LSCs) are responsible for the accumulation of immature malignant cells in the bone marrow. LSCs were considered the ‘bad seeds’, it was showed that AML patients with LSCs enrichment have worse clinical outcomes . Therefore, targeting LSCs by candidate drugs is crucial for AML therapies.
To enable the characterization of genetic heterogeneity in tumor cell populations, we developed a novel microfluidic approach that barcodes amplified genomic DNA from thousands of individual cancer cells confined to droplets. The barcodes are then used to reassemble the genetic profiles of cells from next-generation sequencing data. By using this approach, we sequenced longitudinally collected acute myeloid leukemia (AML) tumor populations from two patients and genotyped up to 62 disease relevant loci across more than 16,000 individual cells. Targeted single-cell sequencing was able to sensitively identify cells harboring …
Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis, Published online: 07 August 2018; doi:10.1038/s41409-018-0288-0Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis
Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21), Published online: 07 August 2018; doi:10.1038/s41408-018-0116-1Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)